Vanrafia (atrasentan) / Chinook Therap, AbbVie, Novartis  >>  Phase 3
Welcome,         Profile    Billing    Logout  

9 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Vanrafia (atrasentan) / Novartis
NCT00271492: Correlation of Endothelial Function and Early Coronary Artery Disease in Humans

Completed
3
200
US
Atrasentan, Xinlay, atrasentan
Mayo Clinic, National Institutes of Health (NIH)
Endothelial Dysfunction
06/06
01/08
NCT00036543: A Study of Atrasentan in Men With Metastatic, Hormone-Refractory Prostate Cancer

Completed
3
1000
US, Canada, Europe, RoW
Atrasentan
Abbott
Prostate Cancer
 
 
NCT00046943: Atrasentan in Treating Patients With Prostate Cancer

Completed
3
US
atrasentan hydrochloride
Abbott
Prostate Cancer
06/07
 
NCT00036556: Study of Atrasentan in Men With Non-Metastatic, Hormone-Refractory Prostate Cancer

Completed
3
941
US, Canada, Europe, RoW
Atrasentan
Abbott
Prostatic Neoplasms
 
 
NCT00134056: S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy

Completed
3
1038
US
atrasentan hydrochloride, atrasentan, docetaxel, taxotere, prednisone, steroid, placebo
Southwest Oncology Group, National Cancer Institute (NCI)
Metastatic Cancer, Prostate Cancer
02/16
02/16
SONAR, NCT01858532 / 2012-005848-21: Study Of Diabetic Nephropathy With Atrasentan

Checkmark Due to lack of enough events to validate the primary endpoint
Dec 2017 - Dec 2017: Due to lack of enough events to validate the primary endpoint
Terminated
3
5107
NA
Atrasentan, ABT-627, Placebo
AbbVie
Diabetic Nephropathy
03/18
03/18
2020-003084-26: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Atrasentan in Patients with IgA Nephropathy at Risk of Progressive Loss of Renal Function (The ALIGN Study)

Completed
3
384
Europe, RoW
atrasentan, [Atrasentan], Film-coated tablet
Chinook Therapeutics U.S., Inc., CHINOOK THERAPEUTICS, U.S., Inc, Chinook Therapeutics U.S., Inc.
Immunoglobulin A Nephropathy (IgAN), Immunoglobulin A Nephropathy (IgAN), Diseases [C] - Immune System Diseases [C20]
 
 
ALIGN, NCT04573478: Atrasentan in Patients With IgA Nephropathy

Active, not recruiting
3
404
Europe, Canada, Japan, US, RoW
Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627, Placebo
Chinook Therapeutics, Inc.
IgA Nephropathy, Immunoglobulin A Nephropathy
12/26
12/26
NCT00127478: A Long Term Safety Study With Atrasentan

Completed
2/3
166
US, Canada, Europe
Atrasentan
Abbott
Prostate Cancer, Adenocarcinoma
 
06/07

Download Options